Author Index to Volume 14

Ackley, A.M., 287
Affrime, M., 93
Alam, K., 509
Albert, M.J., 353, 509
Aldridge, K.E., 361, 377
Allen, S.D., 111, 361
Amsterdam, D., 281
Andrews, J.M., 45
Anhalt, J.P., 185
Appleman, M.D., 311
Arens, M., 125
Ashby, J.P., 45
Ashtekar, D.R., 465
Aubry, P., 447

Baird, D.L., 507
Bale, M., 7
Balows, A., 273, 365
Barlett, J.G., 11
Barr, W.H., 93
Barrett, M.S., 301, 319, 389, 425, 473, 519
Bartholomew, W., 281
Bartlett, R.C., 157, 195
Bauernfeind, A., 63, 89
Brackman, M.A., 29
Briggs, B.M., 301, 319, 389, 425, 473
Briones, F., 331

Canawati, H.N., 297
Cherubin, C.E., 311
Chin, N.-X., 79, 135, 181, 331, 417
Christensen, B., 191
Christensen, M.L., 233
Chun, C.S.Y., 119
Clark, R.B., 173
Clynes, N., 435
Cohen, M.A., 245, 403
Coleman, P., 171
Costa-Periera, R., 465
Crabb, D.M., 265
Criswell, K., 17
Crowe, H., 157
Curtin, N., 17

De la Rosa, M., 515
Dezfulian, M., 11
Doern, G.V., 75, 485
Drulak, M., 281
Duffy, L.B., 265
Dulworth, J.K., 29

El-Mady, A., 141
Erwin, M.E., 301, 319, 383, 389, 425, 473, 519

Espy, M.J., 293
Evans, E., 209
Evans, M.R., 107

Farrel, P., 495
Fasching, C.E., 147
Ferrigno, S.R., 355
Figarola, T.A., 265
Fijalkowski, C., 281
Flint, K.K., 111
Fredrickson, M., 209
Frei, R., 447
Friedman, D.L., 233
Fuchs, P.C., 361

García García, M.I., 239
García Sánchez, E., 239
García Sánchez, J.E., 239
García-Rodríguez, J.A., 239
Gee, S.L., 355
Gerding, D.N., 147
Gerlach, E.H., 361, 383, 485
Ginunas, V., 297
Gobbo, A.F., 367
Gooch, M., 287
Goodman, J.M., 177
Gottschall, R.L., 367
Grotz, R., 157
Gu, J.-W., 79, 135
Gunnersen, N., 281

Hagerty, C.M., 125
Hall, G.S., 511
Hall, R.T., 191
Hartstein, A.I., 275
Heifetz, C.L., 245, 403
Hens, K., 53
Hermans, P.F., 293
Herschman, B., 17
Heseltine, P.N.R., 311
Hohl, P., 447
Holley, K.E., 293
Hollis, R., 209
Hopkins, M.K., 185
Hossain, M.A., 509
Howard, C., 233
Huband, M.D., 245, 403
Hussain, Z., 507

Iyyer, R., 465

Jacobs, J., 53
Janda, J.M., 173
Jemal, C., 17

Jímenez-Alonso, J., 515
Johnson, D.M., 301, 319, 389, 425, 473
Johnson, R.A., 185
Johnston, S.L.G., 131, 373
Jones, R.N., 37, 301, 319, 337, 361, 383, 389, 425, 473, 519
Jorgensen, J.H., 485

Kabir, I., 509
Kaltwasser, G., 259
Kammer, R.B., 101
Kenny, M.T., 29
Kibriya, A.K.M.G., 353
Kim, C.J., 203
Kirupashanker, M.P., 219
Knapp, C.C., 383
Koontz, F.P., 111, 383
Kostman, J., 107
Krajewski, L.P., 167
Krom, R.A.F., 293
Kuriakose, R., 219

Lam, M., 259
LaScolea, L., 281
Leatherdale, C.L., 507
LeBar, W., 17
Leete, J.K., 233
León, J.L., 515
Lerer, T.J., 157, 195
Levin, M.J., 287
Lim, J., 93
Lin, C.-C., 93
Lister, P.D., 173
Locke, L., 107
Loo, V.G., 443
López-López, G., 1
Ludwig, J., 293

Magee, B.B., 459
Magee, P.T., 459
Maharajan, V.S., 219
Mailloux, G.B., 245, 403
Mangano, M.F., 347
Martínez, M.J., 515
Martínez-Martínez, L., 1
Massanari, R.M., 209
Mazens-Sullivan, M.F., 195
McGowan, K.L., 347
Medeiros, A.A., 85
Montgomerie, J.Z., 297
Montiel, G., 259
Moody, J.A., 147
Mortensen, J.E., 141
Morthland, V.H., 275

Muñoz Bellido, J.L., 239
Murray, P.R., 33, 35, 383, 485, 501

Nagaraja, K.V., 203
Neogi, P.K.B., 509
Neu, H.C., 23, 79, 135, 181, 331, 417, 435
Nightingale, C.H., 157
Niles, A.C., 501
Nivar-Aristy, R.A., 167

Orlando, R., 157
Osband, M., 287
Owen, J., 125

Papanicolaou, G.A., 85
Parker, C.A., 225
Pascual, A., 1
Patterson, J.E., 495
Paya, C.V., 293
Perea, E.J., 1
Peterson, L.R., 147
Pfaller, M.A., 7, 209, 361, 383
Pinto, M.E., 259
Plata, J., 515
Platt, D., 157
Podgore, J.K., 287
Poppiti, R.J., Jr., 177
Pratt-Rippen, K., 511

Qadri, F., 353
Quinn, P., 443
Quintiliani, R.D., 157

Radwanski, E., 93
Randall, E.L., 367
Rashad, A.L., 275
Reed, C.A., 125
Ress, R., 101
Reynolds, J.K., 111
Reznicek, M., 7
Rhodes, G., 287
Richardson, S., 443
Rittel, W., 465
Roland, G.E., 245, 403
Rolfzen, M.A., 185
Rudrik, J.T., 355

Salam, A., 353
Sapico, F.L., 297
Schieven, B.C., 507
Schmid, T., 265
Schubiner, H., 17
Schwabe, L.D., 367
Scully, B.E., 435
Shadomy, H.J., 21
Shadomy, S., 21
Sharp, S.E., 177
Sherbeck, M., 17
Sheridan, V.L., 459
Shrinivasan, T., 465
Siddiqi, S.H., 34
Siegel, C.S., 131
Simecka, J.W., 265
Sinn, L.M., 147
Smith, T.F., 293
Smith, W.B., 523
Stein, G.E., 459
Storch, G.A., 125
Stratton, C.W., 311, 377
Strycharz, C., 157
Sumaya, C.V., 287
Symchowicz, S., 93

Tenquist, J., 147
Tetreault, J., 157
Thomas, P.A., 219
Thornber, D., 45
Thornsberry, C., 485
Tosaka, M., 451
Truant, A.L., 107
Turner, R.B., 119
Tzipori, S., 353, 509

Vance, D.W., Jr., 523
Verbist, L., 53
Vishvanathan, B., 465

Waites, K.B., 265
Wakefield, D.S., 209
Washington, J.A., 167, 383, 511
Washington, J.A., Jr., 485
Weber, J.M., 225
Weeks, L.S., 377
Weinstein, M.P., 287
Wiesner, R.H., 293
Winston, C., 281
Wise, R., 45
Wren, C.G., 287

Yamane, N., 337, 451
Yoder, S.L., 245, 403
Yong, J., 281
Yu, K.-W., 331
Yu, P.K.W., 185

Zervos, M.J., 495
Zhang, Y.-X., 417
Zhang, Y.-Z., 23
Zuerlein, T.J., 191

Subject Index to Volume 14

Acinetobacter antiratus, RU29246 activity against, 473–483
Acinetobacter spp.
  fluoroquinolone activity against, 245–258
  OCP 9-176 activity against, 135–140
Acquired immunodeficiency syndrome. *See Candida albicans*
Actinobacillus actinomycetemcomitans, identification with quadFERM+, 185–187
Adherence, effect of siliconized latex urinary catheter on, *Pseudomonas aeruginosa* and *Escherichia coli*, 1–6
Aerobic Gram-positive cocci, trospectomycin activity against, 259–264
Agar dilution technique, determination of antibiotic susceptibilities of *Ureaplasma urealyticum*, 265–271
Agar dilution test, correlation with disk diffusion test results, 447–450
Agar gel enyzme assay
  comparison with microagglutination test and serum plate test, 203–208
  detection of *Salmonella enteritidis* antibodies, 203–208
AGEA. *See* Agar gel enzyme assay
Algorithm, priorities for therapy based on culture results, 157–166
Alkyltrimethylammonium bromide, and plasmid DNA preparations of *Staphylococcus epidermidis*, 275–280
Aminoglycosides, *Edwardsiella tarda* susceptibility to, 173–175
Amoxicillin–clavulanic acid, activity against *Haemophilus influenzae* and *Branhamella catarrhalis* compared with ceftibuten, 75–77
Amphotericin B, *Candida albicans* serotypes A and B susceptibility to, 21–22
Ampicillin
  activity against ampicillin-resistant *Enterococcus faecium*, 141–145
  activity against *Listeria monocytogenes*, 311–317
  Enterococcus faecium resistant to, activity of ampicillin, daptomycin, and vancomycin against, 141–145
Ampicillin/sulbactam, activity against beta-lactamase-producing enterococci, 495–499
Anaerobic bacteria, trospectomycin activity against, 259–264
Antibiotics, cost-effective use, recommendations for in microbiology laboratory reports, 157–166
Antifungals, *Candida albicans* serotypes A and B, comparative study of susceptibility, 21–22
Antimicrobials, DNA probe test for susceptibility of *Legionella pneumophila* to, 7–10
Arteriovenous fistula, infection with *Rothia dentocariosa*, 167–169
Aspergillus spp., diagnosis of mycotic keratitis due to using LPCB mounts of corneal ulcer scrapings, 219–224
AT-4140. *See* Sparfloxacin
Aztreonam, *Edwardsiella tarda* susceptibilities to, 173–175
Aztreonam–clavulanic acid, synergistic activity against *Xanthomonas maltophilia*, 239–243

Bacillus, Gram-negative, isolation of as presumed etiologic agent of cat scratch disease, 511–513
BACTEC 460 TB system, mycobacterial cross-contamination with, 33–35
BACTEC NR660
  blood culture results after five versus seven days of incubation, 177–179
  detection of positive blood cultures by, 107–110
BACTEC PLUS system, comparison with NR BACTEC system, 111–118
BACTEC Standard system, comparison with BACTEC PLUS system, 111–118
Bacteremias, ofloxacin therapy, 435–441
Bacteria, multiply-resistant, ofloxacin therapy of infections due to, 435–441
Bacteriuria, catheter-associated, 1–6
Bacteroides
  classification of from Gram-stained smears, 195–201
  effect of LY26482 on, 181–184
  fleroxacin and rifampin combination effect on, 23–27
Bacteroides fragilis
  cefdinir activity against, 425–434
  cefoxitin-susceptible and -resistant, activity of clindamycin and metronidazole against, 377–382
  classification of from Gram-stained smears, 195–201
  fluoroquinolone activity against, 245–258
  PD127391 activity against, 389–401
  PD131628 activity against, 389–401
  resistant to E-1040, 301–309
  sparfloxacin activity against, 319–330
  susceptibility testing for, 501–505
  trospectomycin activity against, 259–264
Bacteroides melaninogenicus, trospectomycin activity against, 259–264
Beta-lactam/beta-lactamase inhibitor combinations, and antibiotic susceptibility profile of *Xanthomonas maltophilia*, 239–243
Beta-lactamase
  ceftibuten induction of activity in *Enterobacter cloacae, Serratia marcescens, Enterobacter aerogenes*, 85–87
  enterococci-producing, ampicillin–sulbactam activity against, 495–499
  production by *Edwardsiella tarda*, 173–175
  stability of OCP 9-176 to attack by, 135–140
  sulbactam protection against provided to cefoperazone, 147–155
Beta-lactamase hydrolysis, stability of ceftibuten to, 5–52
Beta-lactams, minimum inhibitory concentrations, 337–345
BK-218, activity against *Legionella*, 519–521
Blood culture
  BACTEC PLUS versus BACTEC Standard for detecting microorganisms, 111–118
  five versus seven days of incubation using the BACTEC NR660, 177–179
  positive, detection with BACTEC NR660, 107–110
Bone infections, ofloxacin therapy, 435–441
Book reviews
  Campylobacter pylori in Gastritis and Peptic Ulcer Disease, 365
  Foodborne Listerosis, 273
Botryodiplodia theobromae, diagnosis of keratitis due to by LPCB mounts of corneal scrapings, 219–224
Botulism. *See Clostridium botulinum*
Branhamella catarhallis
  ceftibuten activity against, 75–77
  fluoroquinolone activity against, 245–258
Breast milk, ceftibuten levels in, 93–100

Broth dilution technique, determination of antibiotic susceptibilities of *Ureaplasma urealyticum*, 265–271
Broth microdilution susceptibility test
for *Bacteroides fragilis*, 501–505
Haemophilus influenzae, 485–493
Brucella melitensis, use in immunoblotting test for acute brucellosis, 515–518
Brucellosis, acute, immunoblotting study of serologic response in, 515–518
Bursitis, infected with *Campylobacter jejuni*, 507–508

Campylobacter jejuni
bursitis infected with, 507–508
infection in combination with multiple serotypes of shigella, 353–354
Candida, in pediatric patients, 119–123
Candida albicans
serotypes A and B, antifungal susceptibility, comparative study, 21–22
use of rDNA restriction fragment length polymorphisms to differentiate strains, 459–464
Candidiasis
predictors of in pediatric patients, 119–123
vulvovaginal, use of rDNA restriction fragment length polymorphisms to differentiate strains of *Candida albicans*, 459–464
Candiduria, outcome in pediatric patients, 119–123
Capnocytophaga, identification with quadFERM+, 185–187
Cardiobacterium hominis, identification with quadFERM+, 185–187
Cat scratch disease, isolation of presumed etiologic agent, 511–513
Catheters, siliconized latex urinary, effect of on bacterial adherence and on PMN activity, 1–6
Cefaclor
activity compared with ceftibuten, 53–61
versus ceftibuten, treatment of acute lower respiratory tract infections, 101–105
Cefdinir
activity against *Legionella*, 519–521
in vitro activity evaluations, 425–434
Cefetamet, activity compared with ceftibuten, 53–61
Cefixime, and susceptibility testing for *Neisseria gonorrhoeae*, 383–388
Cefoperazone
activity compared with cefpirome, 361–364
activity in neutropenia site model, 147–155
Cefotaxime, activity compared with cefpirome, 361–364
Cefoxitin, *Bacteroides fragilis* susceptible and resistant to, activity of clindamycin and metronidazole against, 377–382
Cefpirome
activity against *Enterococcus faecalis* pyelonephritis, 297–300
activity compared with third-generation cephalosporins, 361–364
antimicrobial activity, 361–364
combined with gentamicin, activity against *Enterococcus faecalis*-caused pyelonephritis, 297–300
Cefprozil, activity against staphylococci, 63–74
Ceftazidime
activity against *Xanthomonas maltophilia*, 447–450
activity compared with cefpirome, 361–364
resistance of *Xanthomonas maltophilia* to, 239–243
Cefteram, activity compared with ceftibuten, 53–61
Ceftibuten
activity, US and Canadian strains, 37–43
activity against Enterobacteriaceae producing extended spectrum beta-lactamases, 89–92
UK strains, 45–52
West German strains, 63–74
activity against *Haemophilus influenzae* and *Branhamella catarrhalis*, 75–77
activity against multiply-resistant microorganisms, Belgian strains, 53–61
activity compared with amoxicillin–clavulanic acid against *Haemophilus influenzae* and *Branhamella catarrhalis*, 75–77
combination with theophylline, 93–100
combined with Penem SCH 29482, antimicrobial effects, 79–83
Enterococcus faecalis and *Pseudomonas aeruginosa* strains resistant to, Belgian, 53–61
induction of beta-lactamases of *Enterobacter cloacae*, *Serratia marcescens*, and *Enterobacter aerogenes*, 85–87
pharmacokinetics of, 93–100
stability of to beta-lactamase hydrolysis, 45–52
versus cefaclor in acute lower respiratory tract infections, 101–105
Ceftizoxime, activity compared with cefpirome, 361–364
Ceftizoxime disk susceptibility test, and staphylococcal resistance to penicillinase-resistant penicillins, 451–456
Cefuroxime, activity against staphylococci, 63–74
Cell culture
Chlamydia trachomatis detection with, 17–20
detection of influenza A and B virus, 131–134
Cephalosporins. *See also* BK-218; Cefdinir; Cefpirome; Ceftibuten; E-1040; ME-1206; RU29246
activity against *Legionella*, 519–521
Edwardsiella tarda susceptibility to, 173–175
Children, *Rhodococcus equi* infections, 347–352
Chlamydia trachomatis
correlation of positive results in direct fluorescent antibody detection tests with specimen quality, 233–237
detection methods compared, 17–20
immunoassay detection, TestPack *Chlamydia* protocols, 171–172
Chlamydiazyme, results compared with TestPack *Chlamydia* protocol, 171–172
CI-978. *See* Sparfloxacin
CI-983. *See* Cefdinir
Cilofungin, *Candida albicans* serotype A and B susceptibility to, 21–22
Ciprofloxacin
activity against *Xanthomonas maltophilia*, 447–450
Edwardsiella tarda susceptibility to, 173–175
Legionella pneumophila susceptibility to, DNA probe test, 7–10
sparfloxacin combined with, 355–360
Citrobacter, ofloxacin activity against, 435–441
Citrobacter freundii
cefdinir activity against, 425–434
ceftibuten and Penem SCH 29482 activity against, 79–83
ME-1206 activity against, 417–424
OCP 9-176 activity against, 135–140
Clindamycin, activity with metronidazole against cefoxitin-susceptible and -resistant *Bacteroides fragilis*, 377–382
Clostridium
effect of LY264826 on, 181–184

fleroxacin and rifampin combination effect on, 23–27
Clostridium spp., rokitamycin activity against, 331–335
Clostridium botulinum type E, identification by ELISA, 11–15
CMV. *See* Cytomegalovirus
Cocci, Gram-positive
cefpirome activity against, 361–364
sparfloxacin activity against, 355–360
Corynebacterium, identification with quadFERM+, 185–187
Corynebacterium equi. *See Rhodococcus equi*
Corynebacterium jeikeium, identification with quadFERM+, 185–187
Cross-contamination
mycobacterial, with BACTEC 460 TB system, 33–34
with *Mycobacterium tuberculosis* strain lacking nitrate reductase activity, 523–526
Culture results, algorithm priorities for antibiotic therapy based on, 157–166
Cytocentrifuged direct fluorescent antibody, *Chlamydia trachomatis* detection with, 17–20
Cytomegalovirus
diagnosis of hepatitis caused by using histopathology and in situ hybridization, 293–296
recovery of in shell vial culture procedure, 125–130
Cytopathic effect, herpes simplex virus, 373–376
Cytotoxicity, siliconized latex urinary catheters, 1–6

Daptomycin
activity against ampicillin-resistant *Enterococcus faecium*, 141–145
in vitro activity compared with LY264826, 181–184
DFA. *See* Direct fluorescent antibody
Diagnosis, viral infections in Canada 1980–1988, 225–232
Direct fluorescent antibody detection test
correlation of positive *Chlamydia trachomatis* with specimen adequacy, 233–237
cytocentrifuged, *Chlamydia trachomatis* detection with, 17–20
Direct immunofluorescence, detection of influenza A and B virus, 131–134
Disk diffusion susceptiblity test. *See also* E test
correlation with agar dilution test results, 447–450
Haemophilus influenzae, 485–493
DNA probe, for testing antimicrobial susceptibility of *Legionella pneumophila*, 7–10
Doxycycline, activity against *Xanthomonas maltophilia*, 447–450
DuP-721, activity against *Mycobacterium tuberculosis*, 465–471

E test, susceptibility testing for *Bacteroides fragilis*, 501–505
E-1040
activity, 301–309
comparison of activity with other cephalosporins, 301–309
EBV. *See* Epstein-Barr virus
Edwardsiella tarda, in vitro susceptibilities to antibiotics and antibiotic-beta-lactamase inhibitor agents, 173–175
EIA. *See* Enzyme immunoassay
Eikenella corrodens, identification with quadFERM+, 185–187
ELISA. *See* Enzyme-linked immunosorbent assay
Enterobacter aerogenes, ceftibuten induction of beta-lactamase activity, 85–87
Enterobacter cloacae
ceftibuten induction of beta-lactamase activity, 85–87
ceftibuten and Penem SCH 29482 activity against, 79–83
OCP 9-176 activity against, 135–140
Enterobacter spp., ofloxacin activity against, 435–441
Enterobacteriaceae
BACTEC system detection, 111–118
cefoperazone and sulbactam activity against, 147–155
cefpirome activity against, 361–364
ceftazidime activity against, 361–364
ceftibuten activity against, US and Canadian strains, 37–43
ceftibuten activity against, West German strains, 63–74
ceftibuten and Penem SCH 29482 activity against, 79–83
classification of in Gram-stained smears, 195–201
effect of LY264826 on, 181–184
fleroxacin and rifampin combination effect on, 23–27
fluoroquinolone activity against, 245–258
ME-1206 activity against, 417–424
PD127391 activity against, 389–401
PD131628 activity against, 389–401
producing extended spectrum beta-lactamases, ceftibuten activity against, 89–92
RU29246 activity against, 473–483
sparfloxacin activity against, 319–330, 403–415
UK strains, ceftibuten activity against, 45–52
Enterococci
ampicillin-resistant, antimicrobial agents activity against, 337–345
beta-lactamase-producing, ampicillin–sulbactam activity against, 495–499
cefoperazone and sulbactam activity against, 147–155
resistant to E-1040, 301–309
RU29246 activity against, 473–483
teicoplanin activity against, 29–31
vancomycin activity against, 29–31
Enterococcus faecalis
ampicillin–sulbactam activity against, 495–499
cefpirome activity against for pyelonephritis, 297–300
fleroxacin and rifampin combination effect on, 23–27
fluoroquinolone activity against, 245–258
resistant to ceftibuten, Belgian strains, 53–61
sparfloxacin activity against, 355–360, 403–415
Enterococcus faecium, ampicillin-resistant, activity of ampicillin, daptomycin, and vancomycin against, 141–145
Enzyme immunoassay
detection of group-A *Streptococcus* from throat swabs, 281–285
Kallested Pathfinder, *Chlamydia trachomatis* detection with, 17–20
Enzyme-linked immunosorbent assay
and identification of toxigenic *Clostridium botulinum* type E, 11–15
rapid diagnosis of infectious mononucleosis, 287–291
Epidemiological typing techniques, use in identification of MRSA in nosocomial infection clusters, 209–217
Epstein-Barr virus, rapid diagnosis with ELISA, 287–291
Erythromycin, *Legionella pneumophila* susceptibility to, DNA probe test, 7–10
Escherichia coli
effect of siliconized latex urinary catheter on adherence and growth of, 1–6

fleroxacin and rifampin combination effect on, 23–27
OCP 9-176 activity against, 135–140
ofloxacin activity against, 435–441
sparfloxacin activity against, 355–360

Fibroblast cells, human foreskin, and isolation of herpes simplex virus, 373–376
FK482. *See* Cefdinir
Flavobacterium, effect of LY264826 on, 181–184
Fleroxacin
activity against *Xanthomonas maltophilia*, 447–450
combination with rifampin against Enterobacteriaceae and streptococcal species, 23–27
Flucytosine, *Candida albicans* serotype A and B susceptibility to, 21–22
Fluoroquinolones, antibacterial activities, 245–258
Fusarium spp., diagnosis of mycotic keratitis due to using LPCB mounts of corneal scrapings, 219–224
Fusobacterium, effect of LY26482 on, 181–184

GAS. *See* Group-A streptococci
GBS. *See* Group-B streptococci
Genital tract infections, US and Canadian strains, ceftibuten spectrum against, 37–43
Gentamicin
activity against ampicillin-resistant *Enterococcus faecium* in combination with other antimicrobials, 141–145
combined with cefpirome, activity against *Enterococcus faecalis*-caused pyelonephritis, 297–300
Glycopeptides. *See* LY264826
Gram-negative bacilli
cefoperazone activity against, 361–364
cefpirome activity against, 361–364
ceftazidime activity against, 361–364
enteric, ceftizoxime activity against, 361–364
Gram-negative bacteria
BACTEC system detection, 111–118
fluoroquinolone activity against, 245–258
identification with quadFERM+, 185–187
Gram-positive anaerobes, E-1040 activity against, 301–309
Gram-positive bacteria
antimicrobial effects of ceftibuten and Penem SCH 29482 combination, 79–83
fluoroquinolone activity against, 245–258
identification with quadFERM+, 185–187
sparfloxacin activity against, 403–415
vancomycin-resistant, antimicrobial agent activity against, 337–345
Gram-positive cocci
cefpirome activity against, 361–364
sparfloxacin activity against, 355–360
teicoplanin and vancomycin activity against, 29–31
Gram-stained smears, differentiation of Gram-negative rods in, 195–201
Group-A streptococci, detection with TestPack Plus Strep A, 367–372
Group-B streptococci, latex agglutination detection of in urine, 191–194
Growth, effect of siliconized latex urinary catheter on, *Pseudomonas aeruginosa* and *Escherichia coli*, 1–6

HACEK bacteria, identification with quadFERM+, 185–187
Haemophilus
classification of from Gram-stained smears, 195–201
sparfloxacin activity against, 355–360
Haemophilus aphrophilus, identification with quadFERM+, 185–187
Haemophilus influenzae
cefdinir activity against, 425–434
ceftibuten activity against, 75–77, 89–92
West German strains, 63–74
ceftibuten spectrum against, US and Canadian strains, 37–43
ceftibuten versus cefaclor treatment, 101–105
classification of from Gram-stained smears, 195–201
E-1040 activity against, 301–309
fleroxacin and rifampin combination effect on, 23–27
fluroquinolone activity against, 245–258
ME-1206 activity against, 417–424
rokitamycin activity against, 331–335
RU29246 activity against, 473–483
sparfloxacin activity against, 319–330, 403–415
susceptibility tests, 485–493
Haemophilus spp., identification with quadFERM+, 185–187
Haemophilus test medium, use in susceptibility testing, 485–493
HEp-2 cells, and isolation of herpes simplex virus, 373–376
Hepatitis, cytomegalovirus, diagnosis by histopathology and in situ hybridization, 293–296
Herpes simplex virus, isolation of from clinical specimens, 373–376
Histopathology, diagnosis of cytomegalovirus hepatitis, 293–296
HSV. *See* Herpes simplex virus
HTM. *See Haemophilus* test medium

ICI-194008, resistance of *Xanthomonas maltophilia* to, 239–243
Imipenem
activity against *Listeria monocytogenes*, 311–317
Edwardsiella tarda susceptibilities to, 173–175
Immunoassay. *See also* Enzyme-linked immunosorbent assay; Kallested Pathfinder enzyme immunoassay; TestPack Plus Strep A+
identification of toxigenic *Clostridium botulinum* type E by, 11–15
Immunoblotting, and serologic response in patients with acute brucellosis, 515–518
Immunofluorescence. *See also* Enzyme-linked immunosorbent assay
direct, detection of influenza A and B virus, 131–134
rapid diagnosis of infectious mononucleosis, 287–291
In situ hyridization, diagnosis of cytomegalovirus hepatitis, 293–296
Infants, group-B streptococcal infection, 191–194
Infectious mononucleosis, rapid diagnosis of with ELISA, 287–291
Influenza A and B virus, detection by direct immunofluorescence, shell vial culture, and cell culture, 131–134

Kallested Pathfinder enzyme immunoassay, *Chlamydia trachomatis* detection with, 17–20
Keratitis, mycotic, diagnosis with lactophenol cotton blue mounts of corneal scrapings, 219–224
Kingella kingae, identification with quadFERM+, 185–187
Kingella spp., identification with quadFERM+, 185–187
Klebsiella, ofloxacin activity against, 435–441
Klebsiella oxytoca

beta-lactamase hydrolyzes ME-1206, 417–424
OCP 9-176 activity against, 135–140
Klebsiella pneumoniae, OCP 9-176 activity against, 135–140

Laboratory Centre for Disease Control, Canada, diagnosis of viral infections, 225–232
Lactophenol cotton blue, mounts of corneal ulcer scrapings with to diagnose mycotic keratitis, 219–224
Latex agglutination detection, group-B streptococcal inoculum in urine, 191–194
Legionella pneumophila, DNA probe and antimicrobial susceptibility testing, 7–10
Letters to the Editor, 457–458
Listeria monocytogenes
effect of LY264826 on, 181–184
sparfloxacin activity against, 403–415
susceptiblity testing, 311–317
LPA. *See* Latex particle agglutination; Latex agglutination detection
LPCB. *See* Lactophenol cotton blue
LY264826, in vitro activity compared with other glycopeptides and daptomycin, 181–184

Macrolides. *See* Rokitamycin
ME-1206
activity compared with other antimicrobials, 417–424
hydrolyzation of, 417–424
ME-1228, activity compared with OCP 9-176, 135–140
Mean inhibitory concentrations, RU29246, 473–483
Methicillin-resistant *Staphylococcus aureus*, molecular typing, 209–217
Metronidazole, combined with clindamycin, activity against cefoxitin-susceptible and -resistant *Bacteroides fragilis*, 377–382
Microagglutination test, comparison with AGEA and serum plate test, 203–208
Microbial growth, blood culture for five versus seven days using the BACTEC NR660, 177–179
Microbiology laboratory reports, recommendations for antibiotic therapy, 157–166
Microorganisms, detection of in blood with BACTEC NR660, 107–110
Microtrac Direct Specimen Test, positive results for *Chlamydia trachomatis* depend on specimen quality, 233–237
Minimum bactericidal concentrations
cefpirome, 297–300
ceftibuten, 89–92
fleroxacin–rifampin, 23–27
ME-1206, 417–424
Minimum inhibitory concentrations
amikacin, 337–345
aminoglycosides, 173–175
amoxicillin–clavulanate, 485–493
ampicillin, 141–145, 485–493
ampicillin–sulbactam, 485–493, 495–499
antibiotic-beta-lactamase inhibitor agents, 173–175
aztreonam, 173–175, 485–493
BK-218, 519–521
cefamandole, 485–493
cefdinir, 425–434, 519–521
cefixime, 45–52
cefpirome, 297–300, 361–364
cefoperazone, 147–155
ceftibuten, 37–43, 45–52, 53–61, 63–74, 89–92
cefixime, 485–493
cefonicid, 485–493
cefotaxime, 485–493
ceftazidime, 485–493
ceftriaxone, 485–493
cefuroxime, 485–493
cephalosporins, 172–175
chloramphenicol, 337–345, 485–493
ciprofloxacin, 173–175, 485–493
clindamycin, 337–345, 377–382
concentration, E-1040, 301–309
daptomycin, 141–145
erythromycin, 265–271, 337–345
gentamicin, 337–345
glycopeptides, 337–345
fleroxacin, 23–27
imipenem, 173–175, 485–493
LY264826, 181–184
ME-1206, 417–424
minocycline, 337–345
OCP 9-176, 135–140
PD117596, 245–258
PD124816, 245–258
PD127391, 245–258
PD127628, 389–401
PD131628, 389–401
penicillins, 173–175
quinolones, 337–345
ramoplanin, 337–345
rifampin, 337–345, 485–493
RU29246, 519–521
sparfloxacin, 319–330, 355–360, 403–415
SXT, 337–345
teicoplanin, 29–31
tetracycline, 265–271, 485–493
trimethoprim–sulfamethoxazole, 485–493
using *Haemophilus* test medium, 485–493
vancomycin, 29–31, 141–145
Minocycline, in vitro activity
against ampicillin-resistant enterococci, 337–345
against Gram-positive species resistant to vancomycin, 337–345
Molecular probes. *See* Restriction fragment length polymorphisms
Molecular typing techniques, use in identification of nosocomial infection clusters, 209–217
Moraxella catarrhalis
ceftibuten activity against, West German strains, 63–74
ceftibuten spectrum against, US and Canadian strains, 37–43
ceftibuten versus cefaclor treatment, 101–105
E-1040 activity against, 301–309
ME-1206 activity against, 417–424
rokitamycin activity against, 331–335
RU29246 activity against, 473–483
sparfloxacin activity against, 319–330, 403–415
Moraxella spp., identification with quad-FERM+, 185–187
Morganella, beta-lactamase hydrolyzes ME-1206, 417–424
Morganella morganii, cefdinir activity against, 425–434
Moxalactam, resistance of *Xanthomonas maltophilia* to, 239–243
MRSA. *See* Methicillin-resistant *Staphylococcus aureus*
Mycobacteria, and cross-contamination with BACTEC 460 TB system, 33–34
Mycobacterium fortuitum, DuP-721 activity against, 465–471
Mycobacterium gordonae, DrP-721 activity against, 465–471
Mycobacterium kansasii, DuP-721 activity against, 465–471
Mycobacterium scrofulaceum, DuP-721 activity against, 465–471
Mycobacterium tuberculosis
DuP-721 activity against, 465–471
strain lacking nitrate reductase activity, cross-contamination with, 523–526
Mycoplasma pneumoniae, isolation from pleural fluid, 443–445

Mycotic keratitis, diagnosis of with lactophenol cotton blue mounts of corneal scrapings, 219–224

Neisseria gonorrhoeae
ceftibuten activity against, West German strains, 63–74
fluoroquinolone activity against, 245–258
ME-1206 activity against, 417–424
rokitamycin activity against, 331–335
sparfloxacin activity against, 319–330, 403–415
susceptibility testing, 383–388
Neisseria spp.
ceftibuten activity against, UK strains, 45–52
ceftibuten spectrum against, US and Canadian strains, 37–43
E-1040 activity against, 301–309
RU29246 activity against, 473–483
Neutropenic site model, cefoperazone and sulbactam activity in, 147–155
Neutrophils. *See also* Polymorphonuclear leukocytes
effect of siliconized latex urinary catheter on activity of, 1–6
Nosocomial infections. *See* Methicillin-resistant *Staphylococcus aureus*
Nosocomial pathogens. *See Xanthomonas maltophilia*

OCP 9-176
activity compared with sulfur analog and other beta-lactams, 135–140
stability to attack by beta-lactamases, 135–140
Ofloxacin, therapy of infections due to multiply-resistant bacteria, 435–441
Osteomyelitis, ofloxacin therapy, 435–441
Oxalzolidinones. *See also* DuP-721
activity of, 465–471
Oxycephems. *See also* OCP 9-176

PD117596, antibacterial activity, 245–258
PD124816, antibacterial activity, 245–258
PD127391
antibacterial activity, 245–258
antimicrobial activity evaluation, 389–401
PD131501. *See* Sparfloxacin
PD131628, antimicrobial activity evaluations, 389–401
PD134393. *See* Cefdinir
PDM epsilometer, susceptibility test for *Bacteroides fragilis*, 501–505
Penem SCH 29482, combined with ceftibuten, antimicrobial effects, 79–83
Penicillin, activity against *Listeria monocytogenes*, 311–317
Penicillinase-resistant penicillins, susceptibility testing to identify *Staphylococcus aureus* strains resistant and susceptible, 451–456
Penicillins, *Edwardsiella tarda* susceptibility to, 173–175
Peptococci, effect of LY284826 on, 181–184
Peptostreptococci
effect of LY264826 on, 181–184
rokitamycin activity against, 331–335
Pharmacokinetics, ceftibuten, 93–100
Plasmid profile, *Staphylococcus epidermidis*, 275–280
Pleural fluid, isolation of *Mycoplasma pneumoniae* from, 443–445
PMNs. *See* Polymorphonuclear leukocytes
Pneumococci
cefdinir activity against, 425–434
cefoperazone and sulbactam activity against, 147–155
Pneumoniae, *Mycoplasma pneumoniae* in pleural fluid, 443–445
Polymorphonuclear leukocytes, effect of siliconized latex urinary catheter on activity of, 1–6
Proteus vulgaris
beta-lactamase hydrolyzes ME-1206, 417–424
cefdinir activity against, 425–434
OCP 9-176 activity against, 135–140
Providencia spp., sparfloxacin activity against, 319–330
Providencia stuartii, OCP 9-176 activity against, 135–140
PRPs. *See* Penicillinase-resistant penicillins
Pseudomonads, BACTEC detection, 111–118
Pseudomonas aeruginosa
cefdinir activity against, 425–434
cefoperazone and sulbactam activity against, 147–155
classification of from Gram-stained smears, 195–201
E-1040 activity against, 301–309
effect of siliconized latex urinary catheter on adherence and growth of, 1–6
fleroxacin and rifampin combination effect on, 23–27
fluoroquinolone activity against, 245–258
OCP 9-176 activity against, 135–140
ofloxacin activity against, 435–441
PD127391 activity against, 389–401
PD131628 activity against, 389–401
resistance to ceftibuten, Belgian strains, 53–61
resistance to ME-1206, 417–424
sparfloxacin activity against, 319–330
Pseudomonas spp., RU29246 activity against, 473–483
Pyelonephritis, *Enterococcus faecalis*-caused, cefpirome activity against, 297–300

quadFERM+, identification of Gram-positive and Gram-negative bacteria, 185–187
Quinolones. *See also* PD127391; PD131628; Sparfloxacin
activity against ampicillin-resistant enterococci, 337–345
in vitro activity against Gram-positive species resistant to vancomycin, 337–345

RD cells. *See* Rhabdomyosarcoma cells
Resistance, antimicrobial. *See* Susceptibility testing
Respiratory infections. *See also Mycoplasma pneumoniae*
US and Canadian strains, ceftibuten spectrum for, 37–43
Respiratory tract infections
acute lower, ceftibuten versus cefaclor treatment, 101–105
lower
cost-effective use of antibiotics for treatment, 157–166
ofloxacin therapy, 435–441
Restriction fragment length polymorphisms, rDNA, to differentiate strains of *Candida albicans*, 459–464
Rhabdomyosarcoma cells, and isolation of herpes simplex virus, 373–376
Rhodococcus equi, infections in children, 347–352
Rifampin
combination with fleroxacin against Enterobacteriaceae and streptococcal species, 23–27
in vitro activity against ampicillin-resistant enterococci, 337–345
in vitro activity against Gram-positive species resistant to vancomycin, 337–345
Legionella pneumophila susceptibility to, DNA probe test, 7–10
Rokitamycin, antibacterial activity compared with other macrolides, 331–335
Rothia dentocariosa
antimicrobials active against, 167–169

infection of ateriovenous fistula with, 167–169
RU29246
activity against *Legionella*, 519–521
in vitro activity, 473–483

Salmonella, ofloxacin activity against, 435–441
Salmonella enteritidis, AGEA detection of antibodies, 203–208
SE. *See Salmonella enteritidis*
Serratia marcescens
cefdinir activity against, 425–434
ceftibuten and Penem SCH 29482 activity against, 79–83
ceftibuten induction of beta-lactamase activity, 85–87
ME-1206 activity against, 417–424
OCP 9-176 activity against, 135–140
ofloxacin activity against, 435–441
sparfloxacin activity against, 319–330
Serum plate test, comparison with AGEA and microagglutination test, 203–208
Shell vial culture
detection of influenza A and B virus, 131–134
recovery of CMV in, 125–130
Shigella, simultaneous infection with multiple serotypes, 353–354
Shigella boydii, infection with, 353–354
Shigella dysenteriae, infection with, 353–354
Shigella flexneri, infection with, 353–354
Shigellosis, *Vibrio fluvialis* bacteremia associated with, 509–510
Showa disk susceptibility test, and discrimination between *Staphylococcus aureus* strains resistant and susceptible to PRPs, 451–456
Soft tissue infections, ofloxacin therapy, 435–441
Sparfloxacin
activity of, 403–415
against Gram-positive cocci, 355–360
against *Haemophilus*, 355–360
compared with other quinolone compounds, 319–330
combined with ciprofloxacin, 355–360
in vitro activity
against ampicillin-resistant enterococci, 337–345
against Gram-positive species resistant to vancomycin, 337–345
Staphylococci
BACTEC system detection, 111–118
cefoperazone and sulbactam activity against, 147–155
ceftizoxime activity against, 361–364
fleroxacin and rifampin combination effect on, 23–27
oxacillin-resistant, cefdinir activity against, 425–434
resistant to E-1040, 301–309
RU29246 activity against, 473–483
sparfloxacin activity against, 355–360
Staphylococcus aureus
cefdinir activity against, 425–434
E-1040 activity against, 301–309
effect of LY264826 on, 181–184
fleroxacin and rifampin combination effect on, 23–27
methicillin-resistant, molecular typing, 209–217
methicillin-resistant, trospectomycin activity against, 259–264
OCP9-176 activity against, 135–140
oflaxacin activity against, 435–441
oxacillin-resistant, vancomycin and teicoplanin activity against, 29–31
rokitamycin activity against, 331–335
sparfloxacin activity against, 319–330
susceptibility testing to identify strain resistant and susceptible to PRPs, 451–456
Staphylococcus epidermidis
methicillin-resistant, trospectomycin activity against, 259–264
OCP 9-176 activity against, 135–140
oxacillin-sensitive and -resistant, teicoplanin and vancomycin activity against, 29–31
plasmid profiles, 275–280
Staphylococcus haemolyticus
cefpirome activity against, 361–364
oxacillin-resistant, teicoplanin and vancomycin activity against, 29–32
Staphylococcus spp., ceftibuten activity against, UK strains, 45–52
Streptococci
BACTEC system detection, 111–118
beta-hemolytic
cefdinir activity against, 425–434
E-1040 activity against, 301–309
group-A, detection by TestPack Plus Strep A, 367–372
group-B, latex agglutination detection, 191–194
rifampin and fleroxacin combination effect on, 23–27
rokitamycin activity against, 331–335
sparfloxacin activity against, 355–360
teicoplanin activity against, 29–31
vancomycin activity against, 29–31
Streptococcus, group-B, enzyme immunoassay detection of from throat swabs, 281–285
Streptococcus agalactiae
ceftibuten activity against, 53–61
sparfloxacin activity against, 403–415
Streptococcus pneumoniae
ceftibuten activity against, 89–92
Belgian strains, 53–61
West German strains, 63–74
ceftibuten spectrum against, US and Canadian strains, 37–43
ceftibuten versus cefaclor treatment, 101–105
effect of LY264826 on, 181–184
fluoroquinolone activity against, 245–258
rokitamycin activity against, 331–335
sparfloxacin activity against, 403–415
Streptococcus pyogenes
ceftibuten activity against, 53–61
effect of LY264826 on, 181–184
fluoroquinolone activity against, 245–258
sparfloxacin activity against, 403–415
Streptococcus spp., RU29246 activity against, 473–483
Sulbactam, and cefoperazone, activity in neutropenic site model, 147–155
Susceptibility testing
Bacteroides fragilis, 501–505
Candida albicans, 21–22
Haemophilus influenzae, 485–493
Legionella pneumophila, 7–10
Neisseria gonorrhoeae, 383–388
Xanthomonas maltophilia, 447–450
Susceptibility
antibiotic, profile of *Xanthomonas maltophilia*, 239–243
Listeria monocytogenes, 311–317
Ureaplasma urealyticum, 265–271

Teicoplanin
activity against staphylococci and enterococci, 29–31
in vitro activity compared with LY264826, 181–184
TestPack *Chlamydia* protocol
results compared with chlamydiazyme, 171–172
testing times, 171–172
TestPack Plus Strep A, comparison with selective and nonselective culture media for detection of group-A streptococci, 367–372

Tetracycline, activity against *Xanthomonas maltophilia*, 447–450
Theophylline, combination with ceftibuten, 93–100
Throat swabs, Visuwell Strep-A EIA detection of group-A *Streptococcus* from, 281–285
Time-kill kinetic studies, ampicillin–sulbactam for beta-lactamase-producing enterococci, 495–499
TPPSA. *See* TestPack Plus Strep A
Trimethoprim–sulfamethoxazole
  activity against *Listeria monocytogenes*, 311–317
  activity against *Xanthomonas maltophilia*, 239–243, 447–450
Trospectomycin, activity against anaerobic bacteria and aerobic Gram-positive cocci (Chile), 259–264
Tuberculosis. *See also Mycobacterium tuberculosis*
  DuP-721 treatment, 465–471
Typing techniques, molecular, use in identification of nosocomial infection clusters, 209–217

U-63,366F. *See* Trospectomycin
Ureaplasma urealyticum, susceptibility testing, 265–271
Urinary tract infections
  ceftibuten spectrum for, US and Canadian strains, 37–43
  ofloxacin therapy, 435–441
Urine, latex agglutination detection of group-B streptococcal inoculum in, 191–194

Vaginitis, *Candida albicans*, use of rDNA restriction fragment length polymorphisms to differentiate strains, 459–464
Vancomycin
  activity against ampicillin-resistant *Enterococcus faecium*, 141–145
  activity against *Listeria monocytogenes*, 311–317
  activity against streptococci and enterococci, 29–31
  Gram-positive species resistant to, antimicrobial agents tested against, 337–345
  in vitro activity compared with LY264826, 181–184
Virio fluvialis bacteremia, associated with shigellosis, 509–510
Virus, diagnosis of infections, Canada 1980–1988, 225–232
Visuwell Strep-A enzyme immunoassay, comparison with culture for detections of group-A *Streptococcus* from throat swabs, 281–285

Xanthomonas maltophilia
  antibiotic susceptibility profile, 239–243
  methoprim–sulfamethoxazole treatment for, 447–450
  susceptibility testing, 447–450